Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
European Heart Journal - Cardiovascular Imaging · 24.07.2023 · 24 (8) · 1019-1030
DOI: 10.1093/ehjci/jead030 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Imaging, online erschienen am 07.03.2023. Verfasst von René Rettl und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aims
Tafamidis treatment positively affects left ventricular (LV) structure and function and improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). We aimed to investigate the relationship between treatment response and cardiac amyloid burden identified by serial quantitative 99mTc-DPD SPECT/CT. We furthermore aimed to identify nuclear imaging biomarkers that could be used to quantify and monitor response to tafamidis therapy. Methods and results Forty wild-type ATTR-CM patients who underwent 99mTc-DPD scintigraphy and SPECT/CT imaging at baseline and after treatment with tafamidis 61 mg once daily [median, 9.0 months (interquartile range 7.0–10.0)] were divided into two cohorts based on the median (−32.3%) of the longitudinal percent change in standardized uptake value (SUV) retention index. ATTR-CM patients with a reduction greater than or equal to the median (n = 20) had a significant decrease in SUV retention index (P < 0.001) at follow-up, which translated into significant benefits in serum N-terminal prohormone of brain natriuretic peptide levels (P = 0.006), left atrial volume index (P = 0.038), as well as LV [LV global longitudinal strain: P = 0.028, LV ejection fraction (EF): P = 0.027, LV cardiac index (CI): P = 0.034] and right ventricular (RV) [RVEF: P = 0.025, RVCI: P = 0.048] functions compared with patients with a decrease less than the median (n = 20).
Conclusion
Treatment with tafamidis in ATTR-CM patients results in a significant reduction in SUV retention index, associated with significant benefits for LV and RV function and cardiac biomarkers. Serial quantitative 99mTc-DPD SPECT/CT imaging with SUV may be a valid tool to quantify and monitor response to tafamidis treatment in affected patients. Translational perspective 99mTc-DPD SPECT/CT imaging with determination of SUV retention index as part of a routine annual examination can provide evidence of treatment response in ATTR-CM patients receiving disease-modifying therapy. Further long-term studies with 99mTc-DPD SPECT/CT imaging may help to evaluate the relationship between tafamidis-induced reduction in SUV retention index and outcome in patients with ATTR-CM and will demonstrate whether highly disease-specific 99mTc-DPD SPECT/CT imaging is more sensitive than routine diagnostic monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Division of Cardiology, Department of Internal Medicine V, Favoriten Clinic, Kundratstraße 3, 1100 Vienna, Austria.
ORCID-Profile: René Rettl, Theresa-Marie Dachs, Lore Schrutka, Daniel Dalos, Dietrich Beitzke, Christian Loewe, Diana Bonderman
Förderung
- Pfizer
Zitieren
APA
Rettl, R., Wollenweber, T., Duca, F., Binder, C., Cherouny, B., Dachs, T. M., Camuz Ligios, L., Schrutka, L., Dalos, D., Beitzke, D., Loewe, C., Badr Eslam, R., Kastner, J., Hacker, M., & Bonderman, D. (2023). Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. European Heart Journal - Cardiovascular Imaging, 24(8), 1019-1030. https://doi.org/10.1093/ehjci/jead030
Vancouver
Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2023;24(8):1019-1030. doi:10.1093/ehjci/jead030
BibTeX
@article{Rettl2023,
author = {Rettl, René and Wollenweber, Tim and Duca, Franz and Binder, Christina and Cherouny, Bernhard and Dachs, Theresa-Marie and Camuz Ligios, Luciana and Schrutka, Lore and Dalos, Daniel and Beitzke, Dietrich and Loewe, Christian and Badr Eslam, Roza and Kastner, Johannes and Hacker, Marcus and Bonderman, Diana},
title = {Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2023},
volume = {24},
number = {8},
pages = {1019--1030},
doi = {10.1093/ehjci/jead030}
}
EUVIMED